Linnaeus Therapeutics has a total of 18 patents globally, out of which 2 have been granted. Of these 18 patents, more than 83% patents are active. The United States of America is where Linnaeus Therapeutics has filed the maximum number of patents, followed by South Africa, Canada and Australia. Parallelly, The United States of America seems to be the main focused R&D center and also the origin country of Linnaeus Therapeutics.
Linnaeus Therapeutics was founded in the year 2015. Linnaeus Therapeutics is a biotech start up. This Company creates and sells medications for treating cancer.
Do read about some of the most popular patents of Linnaeus Therapeutics which have been covered by us in this article and also you can find Linnaeus Therapeutics patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Linnaeus Therapeutics patent portfolio.
How many patents does Linnaeus Therapeutics have?
Linnaeus Therapeutics has a total of 18 patents globally. These patents belong to 4 unique patent families. Out of 18 patents, 15 patents are active.
How Many Patents did Linnaeus Therapeutics File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Linnaeus Therapeutics Applications Filed | Linnaeus Therapeutics Patents Granted |
| 2023 | 1 | 1 |
| 2022 | 5 | – |
| 2021 | 4 | 1 |
| 2019 | 8 | – |
How many Linnaeus Therapeutics patents are Alive/Dead?
Worldwide Patents
How Many Patents did Linnaeus Therapeutics File in Different Countries?
Countries in which Linnaeus Therapeutics Filed Patents
| Country | Patent |
| United States Of America | 4 |
| South Africa | 2 |
| Canada | 2 |
| Australia | 2 |
| Brazil | 1 |
| Europe | 1 |
| Mexico | 1 |
| New Zealand | 1 |
| Israel | 1 |
Where are Research Centers of Linnaeus Therapeutics Patents Located?
What Percentage of Linnaeus Therapeutics US Patent Applications were Granted?
Linnaeus Therapeutics (Excluding its subsidiaries) has filed 2 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 1 have been granted leading to a grant rate of 50.0%.
Below are the key stats of Linnaeus Therapeutics patent prosecution at the USPTO.
Which Law Firms Filed Most US Patents for Linnaeus Therapeutics?
| Law Firm | Total Applications | Success Rate |
| Mcdonnell Boehnen Hulbert & Berghoff | 2 | 50.0% |
List of Linnaeus Therapeutics patents
| Linnaeus Therapeutics Patents | Title |
| US11760749B2 | Enantiomerically Purified Gper Agonist For Use In Treating Disease States And Conditions |
| US10934277B2 | Enantiomerically Purified Gper Agonist For Use In Treating Disease States And Conditions |
| US20220089576A1 | Enantiomerically Purified Gper Agonist For Use In Treating Disease States And Conditions |
| EP3823617A4 | Enantiomerically Purified Gper Agonist For Use In Treating Disease States And Conditions |
| WO2022245899A3 | Diagnostic Methods And Compositions For Treatment Of Cancer |
| AU2022254072A1 | Oncologic Variations Associated With Cancer And Methods Of Treatment |
| CA3214822A1 | Oncologic Variations Associated With Cancer And Methods Of Treatment |
| AU2019310029A1 | Enantiomerically Purified Gper Agonist For Use In Treating Disease States And Conditions |
| CA3107109A1 | Enantiomerically Purified Gper Agonist For Use In Treating Disease States And Conditions |
| IL280283A | Enantiomerically Purified Gper Agonist For Use In Treating Disease States And Conditions |
| BR112021001031A2 | Compound, Pharmaceutical Composition, Cosmetic Composition, And, Methods To Treat Or Prevent A Disease Or Disorder, To Prevent Or Reduce The Likelihood Of Pregnancy After Sexual Intercourse, To Treat Or Prevent Type 2 Diabetes, To Increase Or Prevent Or Reverse Loss For Skin Pigmentation, Skin Protection And To Treat Or Prevent Cancer, Prevent The Recurrence Of Cancer Or Stop The Progression Of Cancer |
| ZA202309345A | Oncologic Variations Associated With Cancer And Methods Of Treatment |
| NZ804356A | Oncologic Variations Associated With Cancer And Methods Of Treatment |
| MX2021000809A | Enantiomerically Purified Gper Agonist For Use In Treating Disease States And Conditions. |
| ZA202100381A | Enantiomerically Purified Gper Agonist For Use In Treating Disease States And Conditions |
| US20200024262A1 | Enantiomerically Purified Gper Angonist For Use In Treating Disease States And Conditions |
| WO2022216893A1 | Oncologic Variations Associated With Cancer And Methods Of Treatment |
| WO2020023391A1 | Enantiomerically Purified Gper Agonist For Use In Treating Disease States And Conditions |
What are Linnaeus Therapeutics key innovation segments?
What Technologies are Covered by Linnaeus Therapeutics?
The chart below distributes patents filed by Linnaeus Therapeutics